Novel approaches for reducing free light chains in patients with myeloma kidney

Colin A. Hutchison, Joan Bladé, Paul Cockwell, Mark Cook, Mark Drayson, Jean Paul Fermand, Efstathios Kastritis, Robert Kyle, Nelson Leung, Sonia Pasquali, Christopher Winearls

Research output: Contribution to journalArticle

Abstract

Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90% of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.

Original languageEnglish
Pages (from-to)234-243
Number of pages10
JournalNature Reviews Nephrology
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Kidney
Light
Knowledge Management
Paraproteinemias
Kidney Diseases
Standard of Care
Multiple Myeloma
Research
Acute Kidney Injury
Atrophy
Fibrosis
Pathology
Survival
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Hutchison, C. A., Bladé, J., Cockwell, P., Cook, M., Drayson, M., Fermand, J. P., ... Winearls, C. (2012). Novel approaches for reducing free light chains in patients with myeloma kidney. Nature Reviews Nephrology, 8(4), 234-243. https://doi.org/10.1038/nrneph.2012.14

Novel approaches for reducing free light chains in patients with myeloma kidney. / Hutchison, Colin A.; Bladé, Joan; Cockwell, Paul; Cook, Mark; Drayson, Mark; Fermand, Jean Paul; Kastritis, Efstathios; Kyle, Robert; Leung, Nelson; Pasquali, Sonia; Winearls, Christopher.

In: Nature Reviews Nephrology, Vol. 8, No. 4, 04.2012, p. 234-243.

Research output: Contribution to journalArticle

Hutchison, CA, Bladé, J, Cockwell, P, Cook, M, Drayson, M, Fermand, JP, Kastritis, E, Kyle, R, Leung, N, Pasquali, S & Winearls, C 2012, 'Novel approaches for reducing free light chains in patients with myeloma kidney', Nature Reviews Nephrology, vol. 8, no. 4, pp. 234-243. https://doi.org/10.1038/nrneph.2012.14
Hutchison CA, Bladé J, Cockwell P, Cook M, Drayson M, Fermand JP et al. Novel approaches for reducing free light chains in patients with myeloma kidney. Nature Reviews Nephrology. 2012 Apr;8(4):234-243. https://doi.org/10.1038/nrneph.2012.14
Hutchison, Colin A. ; Bladé, Joan ; Cockwell, Paul ; Cook, Mark ; Drayson, Mark ; Fermand, Jean Paul ; Kastritis, Efstathios ; Kyle, Robert ; Leung, Nelson ; Pasquali, Sonia ; Winearls, Christopher. / Novel approaches for reducing free light chains in patients with myeloma kidney. In: Nature Reviews Nephrology. 2012 ; Vol. 8, No. 4. pp. 234-243.
@article{174ce9606a2c4e73a0c689b6bcbae7fb,
title = "Novel approaches for reducing free light chains in patients with myeloma kidney",
abstract = "Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90{\%} of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.",
author = "Hutchison, {Colin A.} and Joan Blad{\'e} and Paul Cockwell and Mark Cook and Mark Drayson and Fermand, {Jean Paul} and Efstathios Kastritis and Robert Kyle and Nelson Leung and Sonia Pasquali and Christopher Winearls",
year = "2012",
month = "4",
doi = "10.1038/nrneph.2012.14",
language = "English",
volume = "8",
pages = "234--243",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Novel approaches for reducing free light chains in patients with myeloma kidney

AU - Hutchison, Colin A.

AU - Bladé, Joan

AU - Cockwell, Paul

AU - Cook, Mark

AU - Drayson, Mark

AU - Fermand, Jean Paul

AU - Kastritis, Efstathios

AU - Kyle, Robert

AU - Leung, Nelson

AU - Pasquali, Sonia

AU - Winearls, Christopher

PY - 2012/4

Y1 - 2012/4

N2 - Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90% of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.

AB - Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90% of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.

UR - http://www.scopus.com/inward/record.url?scp=84859002570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859002570&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2012.14

DO - 10.1038/nrneph.2012.14

M3 - Article

C2 - 22349488

AN - SCOPUS:84859002570

VL - 8

SP - 234

EP - 243

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 4

ER -